HTG Molecular Diagnostics Inc and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. have announced a Master Assay Development, Commercialization and Manufacturing Agreement. This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology.
Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock. “We are very impressed with QIAGEN’s Sample to Insight philosophy and quickly envisioned development and commercial synergies through our combined efforts with pharma,” said TJ Johnson, HTG’s President and Chief Executive Officer.
“Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics and we believe this agreement accelerates both companies’ efforts. We are excited to offer this solution to customers,” added Mr. Johnson.
“HTG’s extraction free technology can add attractive capabilities to QIAGEN’s NGS-based Sample to Insight solutions for applications in pathology where sample often is limited,” said Kai te Kaat, Vice President, Head of Franchise Oncology, Molecular Diagnostics Business Area at QIAGEN.
“The addition of HTG’s technology to our Sample to Insight GeneReader NGS system, and augmented by QIAGEN’s capabilities across NGS workflows, will enable our pharma partners to successfully profile patients including settings where only low sample amounts are available. This capability is of interest in many indication areas but primarily in oncology and immune-oncology applications.”
Source: Story from HTG Molecular Diagnostics Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.